CG:600276 Jiangsu Hengrui Medicine Co., Ltd

JIANGSU HENGRUI MEDICINE CO., LTD. is principally engaged in the manufacturing and distribution of pharmaceutical tablets, injections and raw materials. The Company’s main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, drugs for the treatment of endocrine, antibiotics, infusions and others, including calcium levofolinate infusion, cyclophosphamide infusion, etoposide soft capsules, calcium folinate tablets, irbesartan tablets, bupivacaine hydrochloride infusion, levofloxacin hydrochloride tablets, glucose infusion and sodium chloride infusion, among others. The Company distributes its products primarily in domestic markets.

46.41 CNY
As of 01/17/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Drug Manufacturers-General
Index country:  China
Country of incorporation:  China
IPO date:  10/19/2000
Stock exchange:    Shanghai Stock Exchange
Exchange country:   China
Market cap:   298,373,873,664 CNY
Current dividend yield:   0.36%
Sedol:      6288457

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy